Introduction: The prevalence of incidental
Introduction
18 F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) is an important diagnostic tool in the work up and staging of malignancy. Prior to fusion of PET with low-dose CT, PET was reported as a single entity, as such only findings that were FDGavid could be identified and reported. The majority of published data regarding the prevalence of incidental findings on PET/CT relates to findings that are FDG-avid, and very little has been written about non-FDG-avid findings; that is findings that do not accumulate FDG and are therefore optimally characterized on the low-dose, non-contrast CT.
Whilst CT and MRI can provide exquisite anatomical detail, PET has the ability to assess metabolic activity at the molecular level 1 in both structurally normal and abnormal lesions, thereby helping to differentiate benign and malignant conditions. PET has also proven to be of use in post treatment follow-up of neoplasia, and in detection of recurrent disease. The majority of oncology PET imaging utilizes FDG, a non-physiological radiopharmaceutical analogue of glucose. FDG uptake in malignant cells is attributed to increased glucose utilization due to upregulation of hexokinase activity and overexpression of glucose transporters (GLUT). 1, 2 The rate of cellular FDG uptake, in the setting of both benign and malignant disease, reflects metabolic activity. 1 Increased metabolism and consequently increased FDG uptake is also demonstrated in the setting of infection or inflammation, as such FDG PET can be considered a non-specific marker of metabolic activity. A feature of PET/CT is the acquisition of 'whole-body' imaging. This can result in a vast array of unexpected findings remote from the primary region of abnormality and interest. Incidental second primary malignancies, reported in up to 3.1% of PET/CT, [3] [4] [5] [6] [7] [8] are suspected when focal increased metabolic activity is detected in a location unusual for metastatic spread of the patient's known malignancy, and when not interpreted as a physiological site of uptake. 6 Traditional medicine encourages the formulation of a single, unifying diagnosis, 7 however, multiple comorbidities frequently exist in oncology patients, including both benign and malignant causes, with a higher prevalence of synchronous or metachronous malignancy compared with the healthy. [9] [10] [11] Differences in FDG-avidity between lesions, marked difference in response of lesions to therapy on follow-up PET/CT studies, and the appearance of new lesions after a prolonged disease free-period are important factors when assessing for two or more co-existing malignant processes. The gastrointestinal tract, thyroid gland and lung are the most common sites of incidentally detected malignancy. 6, 12, 13 Co-registered PET/CT provides the benefit of both attenuation correction and improved anatomical localization, 14 assisting with interpretation of sites of abnormal FDG-accumulation which can be challenging on PET alone due to limited spatial resolution. 15 The CT obtained in a PET/CT study is typically of lower radiation dose and does not use IV contrast material. Findings that may affect treatment, however, may be present on the low-dose CT and not identifiable on PET alone or fused PET/CT images. Positron emission tomography-computed tomography is most frequently performed in assessment of patients with suspected or established malignancy, thus the manner in which unexpected findings are followed-up may differ from incidental findings discovered on other imaging studies. Factors contributing to this decision include the stage of the known primary and expected prognosis, the patient's age, the location of the incidental finding, medical co-morbidities, difficulties and limitations in performing further imaging, and the preferences of the patient and oncologist. 2 
Methods

Patient population
Five hundred consecutive patients who underwent oncology 'whole body' PET/CT commencing in January 2016 at St Vincent's Hospital, Melbourne were included in this study. All patients were aged 18 years and over at the time of imaging. For patients with more than 1 PET/CT during the study period, only the first study was included in the analysis.
Institutional review board approval was gained for this retrospective study.
Image acquisition
Patients fasted for at least 6 hours prior to the study and received an intravenous injection of~10 MBq/BMI of FDG. Serum blood glucose level was assessed prior to FDG administration. Patients were instructed to lie in a quiet room without talking during the subsequent 50-60 minute FDG uptake phase and were allowed to breathe normally during the image acquisition, without specific instruction.
Patients were imaged on a GE Discovery 710 PET/CT (General Electric Medical Systems, Milwaukee, Wisconsin) combining a 64 slice multidetector CT scanner with a dedicated, full ring PET scanner with lutetium oxyorthosilicate crystals. Image acquisition for the whole body scan commenced 60 minutes AE 10 minutes after the administration of FDG. Whole body emission scans (Vertex to upper thighs) included 7-8 bed positions for 3 minutes in each position. The CT transmission scan was acquired using a low-dose protocol (120 kVp and automatic exposure control ('SmartmA', max 200 mA) without oral or intravenous CT contrast. Total imaging time was approximately 25 minutes.
Computed tomography data was used for anatomical localization and attenuation correction of PET images, and images were reconstructed using General Electric's Q-Clear reconstruction algorithm which incorporated order subset expectation maximization (OSEM) and point spread function. Image fusion was performed using coordinate based fusion software.
The maximum SUV were automatically generated according to the following equation: SUV max (bw) = C tis / D inj /bw, where SUV max (bw) is the maximum SUV normalized for the body weight, C tis is tissue concentration expressed as megabecquerels per millilitre, D inj is injected dose expressed as megabecquerels, and bw is body weight expressed as kilograms.
Data collection and analysis
Two radiologists retrospectively reviewed 500 'wholebody' consecutive cases. One radiologist had additional qualification as a nuclear medicine physician and the other was an advanced nuclear medicine trainee at the time of data collection.
Evaluation of the low-dose CT included standard review of soft tissue, lung and bone windows, as is our routine practise in the axial plane in 5 mm slice thickness.
Images were reviewed at a workstation that provided multiplanar reformatted images and displayed PET, CT and fused PET/CT images.
Definition of incidental findings
An incidental finding was defined as any unknown or unexpected abnormality detected, other than the known primary pathology as documented by the referring clinician, which did not accumulate significant FDG (measured as less than physiological hepatic uptake). Incidental findings were documented and given a category of minor or no significance, moderate significance, or potentially major significance.
Categorization of each abnormality was somewhat arbitrary, but modelled on similar studies. In cases in which the two radiologists recorded different findings, these were later reviewed and a decision was reached based on consensus. Any incidental finding that required further assessment (clinical, histological or radiological) was classified as being of at least moderate significance.
Findings of potentially major significance included suspected additional malignancies, metastatic lesions (including pulmonary nodules 6 mm or larger), and other abnormalities such as vascular dilatation (>4 cm for thoracic aorta), aneurysms (>5 cm for thoracic aorta and >3 cm for abdominal aorta), pneumothorax, pleural or pericardial effusions which required prompt clinical assessment or intervention.
Findings of moderate significance required further correlation with other clinical or imaging findings/work-up. Some of these findings required eventual medical treatment. Pulmonary nodules less than 6 mm were included in this group. Many findings of moderate significance may still be benign or possibly have no clinical impact in an oncology patient. Insignificant findings or findings of minor significance included those not requiring additional work-up. Simple renal and hepatic cysts are an example of these findings.
A final category was given taking into account the availability of previous imaging studies. Any finding that could be identified on previous imaging was assigned into the category of no incidental finding. Any finding that would be expected based on the clinical information was also assigned into this category (e.g. splenomegaly in lymphoma). If a patient had multiple incidental findings that were placed into different categories, only the highest category was used.
Any study that was performed for the purpose of evaluation of solitary pulmonary nodule, or for the staging of non-small cell lung carcinoma (NSCLC) did not include additional pulmonary nodules/masses identified as incidental findings, as each of these patients had recent CT chest prior to PET/CT, and therefore pulmonary nodules had already been documented.
Statistical analysis
Statistical analysis was performed using Microsoft excel, Microsoft Access, and Fisher's exact test. A P-value of <0.05 was considered statistically significant.
Results
F-fluorodeoxyglucose PET/CT was performed in 500
patients between January and August 2016 (242 men, 258 women, mean age 62) for known or suspected malignancy, including evaluation of solitary pulmonary nodule (SPN) ( Table 1) .
Incidental findings were encountered in 463 of 500 patients (92.6%). After reviewing previous imaging studies, it was established that the incidental findings in 237 of these 500 patients (47.4%) were previously unknown.
Findings of potentially major significance were present in 113 of 500 patients (22.6%) pre-review of previous imaging studies, and in 35 patients (7.0%) these findings were considered previously unknown. The most common of these findings were pulmonary nodules 6 mm or larger (9 of 500 patients, 1.8%), pleural effusions of at least moderate size (8 of 500 patients, 1.6%), and dilated/aneurysmal aorta (8 of 500 patients, 1.6%) ( Table 2 ; Figs 1-5) .
Findings of potentially major clinical significance were found in 21 of 242 (8.7%) male patients and 14 of 258 (5.4%) female patients (Table 3) .
Unknown incidental findings of potentially major significance were most common in patients with melanoma, identified in 5 of 17 (29.4%) patients. Patients with melanoma were more likely to demonstrate incidental nonavid findings of potentially major significance compared with all other tumour types combined, (29.4% vs 6.2%, P = 0.004) ( Table 4) .
Of the 35 patients with unknown findings of potentially major clinical significance, management was altered in 23 patient patients in the form of a new intervention (seven patients), follow-up imaging specifically assessing the incidental finding (eight patients), change in medication/chemotherapy regime (four patients), or review by a new specialist team (two patients requiring ongoing haematology review for incidental splenomegaly and two patients requiring ongoing vascular surgery review for incidental aneurysms). Of the 12 patients whose management was not altered, the majority of patients were of advanced stage disease. In several patients a followup PET/CT within 12 months demonstrated stability of the incidental finding, after which no further follow-up had been performed (Table 5 ).
Discussion
18
F-fluorodeoxyglucose PET is an imaging modality that has been used in diagnosis, staging and follow-up of malignancy for over 20 years. In the early 2000s, hybrid PET/CT supplanted stand-alone PET, introducing low-dose CT throughout nuclear medicine. The issues related to potential non FDG-avid findings on the low dose coregistered CT have rarely been discussed in the literature, and this is the largest study of its kind. In Australia FDG PET/CT attracts a Medicare rebate for several malignancies including head and neck carcinoma, melanoma, NSCLC, lymphoma, sarcoma and colorectal carcinoma recurrence. In addition, assessment of solitary pulmonary nodules can attract a Medicare rebate. All of the aforementioned indications were present in our study population.
Osman et al. 15 PET/CT studies used in the diagnostic work-up of lung carcinoma. Of the 321 patients in their study, 263 (82%) had incidental non-avid pathological findings present on the CT component, but in only 43 patients (13%) were these considered of major importance. In 39 of the 43 patients, the abnormality of major significance was already known, highlighting the importance of reviewing all available previous imaging. Therefore in only 4 of 321 patients (one renal metastasis, two cerebral metastasis and one 6.7 cm AAA) did the low-dose CT demonstrate findings that would not have been identified on PET alone, and were unknown prior to the study. Similar to previous similar studies assessing FDG PET/ CT, SPECT/CT, CT coronary angiography (CTCA) and CT colonography (CTC), the majority of incidental findings identified in this study were clinically insignificant or of minor significance, and did not require additional workup. The most common of these findings were minor coronary artery calcification, colonic diverticulosis and cholelithiasis, whilst other findings of minor significance such as adrenal adenomas, lipomas and ovarian cysts could also be categorically diagnosed and characterized on the low-dose CT. The overall rate of incidental findings (463 of 500, 92.6%) is similar but higher than published in other studies such as that of Bruzzi et al. (263/321, 82%). Similar to Bruzzi et al., a large percentage of overall non-avid findings and the vast majority of nonavid findings of major significance had already been established in previous imaging studies. Bruzzi et al.
14 described detection of incidental non FDG-avid findings in patients with malignant disease as 'most likely having no clinical benefit'. Whilst the indications for PET/CT may introduce a selection bias for patients with a lower life expectancy who may ultimately not benefit from discovery of incidental findings, occasionally symptoms can develop from these pathologies of minor significance and it is worthwhile that the treating clinician is aware of their existence. As such, Bruzzi described documenting findings of minor significance on PET/CT as being 'in accordance with good clinical care'. 14 In our study, the prevalence of overall incidental findings of 92.6% is higher than any published study demonstrating extracolonic or extracardiac findings, which is expected given imaging is performed from skull vertex to at least mid-thighs in PET/CT, as opposed to smaller fields of view with CTCA and CTC. In the largest study of its kind, Yap et al. 16 detected incidental findings in 71.9% of 2449 patients imaged for a variety of nuclear medicine studies that utilized SPECT/CT, however, the number of 'important findings' was much lower at 8.7%. In our study, patients with melanoma were considerably more likely to have incidental non FDG-avid findings of potentially major clinical significance (29.4% vs 6.2%, P = 0.004). This statistically significant difference likely reflects that melanoma is infrequently staged with CT prior to PET/CT, as such a higher number of incidental findings identified on PET/CT are unknown.
A large number of detected incidental findings of potentially major significance in our study were pulmonary nodules 6 mm or larger. In 40 of 500 (8.0%) patients, at least one pulmonary nodule 6 mm or larger was detected, however in 31 of these patients the nodule/s had already been detected on previous imaging studies. Of the nine patients with unknown non-avid nodules 6 mm or larger, follow-up studies demonstrated size progression in three patients consistent with metastases. Little data is available regarding the significance of 17 determined that 19% of non-avid pulmonary nodules 10 mm or smaller on PET/CT were malignant upon follow-up. However, as PET/CT technology has evolved since this earlier study, the sensitivity for detecting metabolic activity associated with small pulmonary nodules has improved. We acknowledge that most non-avid incidentally detected nodules in our study are likely benign, and this potential over-estimation of clinical significance may be a limitation of our study. Pleural effusions of moderate or large size were identified in eight patients (1.6%), seven of whom underwent therapeutic pleurocentesis. A clinically significant pleural effusion was the most common finding to progress to an invasive/interventional procedure.
In eight patients (1.6%), unknown non-avid aortic dilatation/aneurysm was detected, including large ascending aortic, descending thoracic aortic, and abdominal aortic aneurysms. Studies assessing extracolonic findings in CT colonography have determined that AAA is a common incidental finding, often the most common significant finding 18, 19 with one author stating that AAA, as opposed to extracolonic malignancies, may serve as the largest benefit in detecting extracolonic findings on CTC. 20 The total number of vascular dilatation/aneurysm represents only a portion of the actual prevalence of incidental AAA in our study sample; many AAA were FDG-avid, usually attributed to inflammation within the vessel wall. At 12 months follow-up, none of the eight patients had undergone surgery for the identified vascular dilatation/aneurysm, however, two had been reviewed by the vascular surgery unit in the outpatient setting. Whilst the CT component of PET/CT is often not formally reported, it is imperative that it is systemically reviewed by the reporting specialist, in particular if previous imaging has not been performed. As our study has demonstrated, this is most important in melanoma studies, in which diagnostic CT of the neck, chest, abdomen, and pelvis is usually not performed prior to PET/CT, resulting in a greater prevalence of unknown non FDGavid findings of potential clinical significance. Should PET/CT ever replace diagnostic CT, a trend that is emerging in lymphoma follow-up, careful review of the CT component will become more important.
Whether formal reporting of incidental findings should take place has still not been defined in the literature. In recent times, much attention has been brought to the increasing number of incidental findings encountered on imaging tests, that often leads to a cascade of further investigations. It is becoming increasing clear that if unexpected findings are described in reports, guidelines should also be provided to the referring physician to enable appropriate follow-up, or in many cases, advise no follow-up at all.
A potential limitation of this study is the short term follow-up on our patients (12 months). Follow-up of lung nodules requires in many cases 24 months of imaging to assess for nodule growth or size stability. This was not done in our study, as such it is not possible to determine the absolute number of lung neoplasms detected incidentally that are not FDG-avid. However, the goal of this study was not only to follow the outcome of abnormalities detected, but to determine the prevalence of significant findings which required additional clinical or radiological follow-up.
This study has not examined the financial implications of further imaging associated with detection of non FDGavid findings on PET/CT. Many studies have analysed the prevalence of incidental findings, but few have analysed the downstream economic effect of work-ups resulting from their discovery. Assessing the financial impact of Fig. 3 . Fifty-nine year old male undergoing PET/CT for recurrence of laryngeal SCC. The liver was noted to have a nodular surface consistent with cirrhosis. This was a previously unknown finding. Fig. 4 . Sixty-nine year old male undergoing PET/CT for staging of buccal mucosa SCC. Fifty five millimeter infrarenal AAA was an unknown finding. This was associated with only very minor FDG-uptake (lower than physiological hepatic uptake).
work-up of incidental findings was beyond the scope of our study, but is certainly a factor that requires consideration.
We have not examined whether low-dose CT can replace diagnostic CT, the latter often performed in addition to PET/CT. Whilst FDG PET/CT provides information that is not obtained in a diagnostic contrast-enhanced CT, the converse is also true. Low-dose, non-contrast CT provides additional information to that provided by metabolic imaging, but in the absence of IV contrast and with suboptimal resolution, it is not likely to identify all findings that may be demonstrated on a diagnostic quality CT. Whether it is able to identify 'clinically significant' findings as accurately as diagnostic quality CT, however, is a topic for future research.
A limitation of this study is that patient's staging was not taken into account when identifying the potentially major incidental finding. As such a number of findings identified as potentially clinically significant were unlikely to be acted on in those patients with advanced disease, e.g. vascular aneurysms in patients with stage 4 malignancy.
In conclusion, the prevalence of incidental findings of major clinical significance that do not accumulate FDG in PET/CT is not insignificant. Incidental findings were detected in 92.6% of patients of which 47.4% were previously unknown. 7.0% (35 patients) had incidental non-avid findings of potentially major clinical significance, and several underwent further imaging, interventional procedures or had alterations in chemotherapy regime due to this incidental discovery. The high prevalence of incidental findings reflects the 'whole-body' nature of FDG PET imaging. Not systematically reviewing the low-dose CT raises the possibility of missing clinically important findings, particularly pleural effusions, vascular aneurysms and metastatic pulmonary nodules.
In many patients, clinical outcomes are not impacted by the detection of avid or non-avid incidental findings as their primary malignancy is advanced. Careful comparison with prior studies helps avoid unnecessary follow-up, as does unequivocal follow-up guidelines for the referring doctor. 
